The historical rank and industry rank for Royalty Pharma's Days Inventory or its related term are showing as below:
FRA:RPD's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.875 * Ranked among companies with meaningful Days Inventory only.
Royalty Pharma's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Royalty Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.00.
Royalty Pharma (FRA:RPD) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Royalty Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Royalty Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Royalty Pharma Days Inventory Related Terms
Royalty Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RPD vs ROIV, MRNA, BNTX: Days Inventory Comparison
For the Biotechnology subindustry, Royalty Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (FRA:RPD) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #999999 out of 638 companies in the Biotechnology industry.
Is Royalty Pharma's Days Inventory too high?
Royalty Pharma's current Days Inventory is 0.00. Based on the distribution chart, Royalty Pharma ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Royalty Pharma has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Days Inventory compare to ROIV and MRNA?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #999999 out of 638 companies for Days Inventory. This places Royalty Pharma in the lower half of its industry. The industry median Days Inventory is 183.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €31.41, compared to a current price of €47.80 — trading 52.2% above its estimated fair value. The current Days Inventory is 0.00. Royalty Pharma's overall GF Score™ is 70/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (FRA:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €47.80 is trading 52.2% above its estimated GF Value™ of €31.41.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for FRA:RPD:
Days Inventory: 0.00
GF Value™: €31.41 vs. price of €47.80 (52.2% above fair value)
No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
70GF Score
Get the complete analysis for FRA:RPD
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RPD has been successfully added to your 
